{"id":4251,"date":"2026-09-05T17:03:18","date_gmt":"2026-09-05T14:03:18","guid":{"rendered":"https:\/\/wniss.com\/?p=4251"},"modified":"2026-09-05T17:04:11","modified_gmt":"2026-09-05T14:04:11","slug":"reviewing-clinical-advances-in-latest-antidepressants-2022","status":"publish","type":"post","link":"https:\/\/wniss.com\/en-gb\/reviewing-clinical-advances-in-latest-antidepressants-2022\/","title":{"rendered":"Reviewing Clinical Advances in Latest Antidepressants 2022"},"content":{"rendered":"<figure class=\"wch-inserted-image\"><img decoding=\"async\" width=\"1024\" height=\"683\" src=\"https:\/\/wniss.com\/wp-content\/uploads\/2026\/09\/reviewing-clinical-advances-in-latest-antidepressants-2022-1-lQLCI6-1024x683.webp\" alt=\"Reviewing Clinical Advances in Latest Antidepressants 2022 - Reviewing Clinical Advances in Latest\" loading=\"lazy\" class=\"wp-image-6091\" title=\"\" srcset=\"https:\/\/wniss.com\/wp-content\/uploads\/2026\/09\/reviewing-clinical-advances-in-latest-antidepressants-2022-1-lQLCI6-1024x683.webp 1024w, https:\/\/wniss.com\/wp-content\/uploads\/2026\/09\/reviewing-clinical-advances-in-latest-antidepressants-2022-1-lQLCI6-300x200.webp 300w, https:\/\/wniss.com\/wp-content\/uploads\/2026\/09\/reviewing-clinical-advances-in-latest-antidepressants-2022-1-lQLCI6-150x100.webp 150w, https:\/\/wniss.com\/wp-content\/uploads\/2026\/09\/reviewing-clinical-advances-in-latest-antidepressants-2022-1-lQLCI6-100x67.webp 100w, https:\/\/wniss.com\/wp-content\/uploads\/2026\/09\/reviewing-clinical-advances-in-latest-antidepressants-2022-1-lQLCI6-200x133.webp 200w, https:\/\/wniss.com\/wp-content\/uploads\/2026\/09\/reviewing-clinical-advances-in-latest-antidepressants-2022-1-lQLCI6-250x167.webp 250w, https:\/\/wniss.com\/wp-content\/uploads\/2026\/09\/reviewing-clinical-advances-in-latest-antidepressants-2022-1-lQLCI6-350x233.webp 350w, https:\/\/wniss.com\/wp-content\/uploads\/2026\/09\/reviewing-clinical-advances-in-latest-antidepressants-2022-1-lQLCI6-400x267.webp 400w, https:\/\/wniss.com\/wp-content\/uploads\/2026\/09\/reviewing-clinical-advances-in-latest-antidepressants-2022-1-lQLCI6-500x333.webp 500w, https:\/\/wniss.com\/wp-content\/uploads\/2026\/09\/reviewing-clinical-advances-in-latest-antidepressants-2022-1-lQLCI6-600x400.webp 600w, https:\/\/wniss.com\/wp-content\/uploads\/2026\/09\/reviewing-clinical-advances-in-latest-antidepressants-2022-1-lQLCI6.webp 1200w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n<div class=\"markdown prose dark:prose-invert wrap-break-word w-full light markdown-new-styling\"><h2><span class=\"ez-toc-section\" id=\"Reviewing_Clinical_Advances_in_Latest_Antidepressants_2022\"><\/span>Reviewing Clinical Advances in Latest Antidepressants (2022)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The year 2022 marked an important period in antidepressant research. While traditional <strong>SSRIs<\/strong>, <strong>SNRIs<\/strong>, and related medications remained the foundation of treatment for major depressive disorder (MDD), researchers increasingly focused on faster-acting therapies, novel mechanisms of action, personalized treatment strategies, and medications that improve symptoms beyond mood alone. <span class=\"\"><span class=\"ms-1 inline-flex max-w-full items-center select-none relative top-[-0.094rem] translate-y-0.5 animate-[show_150ms_ease-in]\" style=\"width: 116px;\"><span class=\"flex h-4.5 overflow-hidden rounded-xl pe-2 ps-1 text-[9px] font-medium transition-colors duration-150 ease-in-out text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]! select-none\"><span class=\"relative start-0 bottom-0 flex h-full w-full items-center\"><span class=\"flex h-4 w-full items-center justify-between\" style=\"opacity: 1; transform: none;\"><span class=\"flex min-w-0 flex-1 items-center gap-1\"><span class=\"inline-flex shrink-0 items-center justify-center overflow-hidden rounded-full\"><\/span><span class=\"max-w-[15ch] grow truncate overflow-hidden text-center\">PMC<\/span><\/span><span class=\"-me-1 flex h-full items-center rounded-full px-1 text-[#8F8F8F]\">+1<\/span><\/span><\/span><\/span><\/span><\/span><\/p><div id=\"ez-toc-container\" class=\"ez-toc-v2_0_88 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/wniss.com\/en-gb\/reviewing-clinical-advances-in-latest-antidepressants-2022\/#Reviewing_Clinical_Advances_in_Latest_Antidepressants_2022\" >Reviewing Clinical Advances in Latest Antidepressants (2022)<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/wniss.com\/en-gb\/reviewing-clinical-advances-in-latest-antidepressants-2022\/#Major_Clinical_Advances\" >Major Clinical Advances<\/a><ul class='ez-toc-list-level-4' ><li class='ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/wniss.com\/en-gb\/reviewing-clinical-advances-in-latest-antidepressants-2022\/#1_Shift_Beyond_the_Monoamine_Hypothesis\" >1. Shift Beyond the Monoamine Hypothesis<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/wniss.com\/en-gb\/reviewing-clinical-advances-in-latest-antidepressants-2022\/#2_Growing_Interest_in_Rapid-Acting_Antidepressants\" >2. Growing Interest in Rapid-Acting Antidepressants<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/wniss.com\/en-gb\/reviewing-clinical-advances-in-latest-antidepressants-2022\/#3_Emerging_Oral_Medications\" >3. Emerging Oral Medications<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/wniss.com\/en-gb\/reviewing-clinical-advances-in-latest-antidepressants-2022\/#4_Focus_on_Cognitive_Symptoms\" >4. Focus on Cognitive Symptoms<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/wniss.com\/en-gb\/reviewing-clinical-advances-in-latest-antidepressants-2022\/#5_Personalized_Depression_Treatment\" >5. Personalized Depression Treatment<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/wniss.com\/en-gb\/reviewing-clinical-advances-in-latest-antidepressants-2022\/#Understanding_Newer_FDA-Approved_Oral_Antidepressants\" >Understanding Newer FDA-Approved Oral Antidepressants<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/wniss.com\/en-gb\/reviewing-clinical-advances-in-latest-antidepressants-2022\/#Clinical_Challenges_Highlighted_in_2022\" >Clinical Challenges Highlighted in 2022<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/wniss.com\/en-gb\/reviewing-clinical-advances-in-latest-antidepressants-2022\/#Research_Pipeline\" >Research Pipeline<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/wniss.com\/en-gb\/reviewing-clinical-advances-in-latest-antidepressants-2022\/#Clinical_Takeaway\" >Clinical Takeaway<\/a><\/li><\/ul><\/nav><\/div>\n\n<h3><span class=\"ez-toc-section\" id=\"Major_Clinical_Advances\"><\/span>Major Clinical Advances<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<h4><span class=\"ez-toc-section\" id=\"1_Shift_Beyond_the_Monoamine_Hypothesis\"><\/span>1. Shift Beyond the Monoamine Hypothesis<span class=\"ez-toc-section-end\"><\/span><\/h4>\n<p>For decades, antidepressant development primarily targeted serotonin, norepinephrine, and dopamine. In 2022, research increasingly explored alternative biological pathways, including:<\/p>\n<ul>\n<li>\n<p>Glutamate signaling<\/p>\n<\/li>\n<li>\n<p>NMDA receptor modulation<\/p>\n<\/li>\n<li>\n<p>Neuroplasticity<\/p>\n<\/li>\n<li>\n<p>Brain-derived neurotrophic factor (BDNF)<\/p>\n<\/li>\n<li>\n<p>Inflammation and immune mechanisms<\/p>\n<\/li>\n<\/ul>\n<p>These approaches aim to produce faster symptom improvement and help patients who do not respond to conventional antidepressants. <span class=\"\"><span class=\"ms-1 inline-flex max-w-full items-center select-none relative top-[-0.094rem] translate-y-0.5 animate-[show_150ms_ease-in]\" style=\"width: 116px;\"><span class=\"flex h-4.5 overflow-hidden rounded-xl pe-2 ps-1 text-[9px] font-medium transition-colors duration-150 ease-in-out text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]! select-none\"><span class=\"relative start-0 bottom-0 flex h-full w-full items-center\"><span class=\"flex h-4 w-full items-center justify-between\" style=\"opacity: 1; transform: none;\"><span class=\"flex min-w-0 flex-1 items-center gap-1\"><span class=\"inline-flex shrink-0 items-center justify-center overflow-hidden rounded-full\"><\/span><span class=\"max-w-[15ch] grow truncate overflow-hidden text-center\">PubMed<\/span><\/span><span class=\"-me-1 flex h-full items-center rounded-full px-1 text-[#8F8F8F]\">+1<\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n<h3><span class=\"ez-toc-section\" id=\"2_Growing_Interest_in_Rapid-Acting_Antidepressants\"><\/span>2. Growing Interest in Rapid-Acting Antidepressants<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Traditional antidepressants often require 4\u20138 weeks before producing substantial benefits.<\/p>\n<p>Clinical studies in 2022 highlighted rapid-acting treatments such as:<\/p>\n<ul>\n<li>\n<p>Esketamine nasal spray<\/p>\n<\/li>\n<li>\n<p>Ketamine infusion<\/p>\n<\/li>\n<li>\n<p>Dextromethorphan-based therapies<\/p>\n<\/li>\n<li>\n<p>Novel glutamatergic compounds<\/p>\n<\/li>\n<\/ul>\n<p>These treatments demonstrated symptom improvement within hours to days in some patients with treatment-resistant depression. <span class=\"\"><span class=\"ms-1 inline-flex max-w-full items-center select-none relative top-[-0.094rem] translate-y-0.5 animate-[show_150ms_ease-in]\" style=\"width: 62px;\"><span class=\"flex h-4.5 overflow-hidden rounded-xl pe-2 ps-1 text-[9px] font-medium transition-colors duration-150 ease-in-out text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]! select-none\"><span class=\"relative start-0 bottom-0 flex h-full w-full items-center\"><span class=\"flex h-4 w-full items-center justify-between\" style=\"opacity: 1; transform: none;\"><span class=\"flex min-w-0 flex-1 items-center gap-1\"><span class=\"inline-flex shrink-0 items-center justify-center overflow-hidden rounded-full\"><\/span><span class=\"max-w-[15ch] grow truncate overflow-hidden text-center\">PMC<\/span><\/span><span class=\"-me-1 flex h-full items-center rounded-full px-1 text-[#8F8F8F]\">+1<\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n<h3><span class=\"ez-toc-section\" id=\"3_Emerging_Oral_Medications\"><\/span>3. Emerging Oral Medications<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Several investigational medications showed encouraging Phase II or Phase III trial results.<\/p>\n<p>Examples included:<\/p>\n<ul>\n<li>\n<p><strong>AXS-05 (dextromethorphan + bupropion)<\/strong><\/p>\n<\/li>\n<li>\n<p>Ansofaxine<\/p>\n<\/li>\n<li>\n<p>MIJ821<\/p>\n<\/li>\n<li>\n<p>Other NMDA-related compounds<\/p>\n<\/li>\n<\/ul>\n<p>Many of these drugs were designed to provide:<\/p>\n<ul>\n<li>\n<p>Faster onset<\/p>\n<\/li>\n<li>\n<p>Better efficacy<\/p>\n<\/li>\n<li>\n<p>Improved tolerability<\/p>\n<\/li>\n<li>\n<p>Different mechanisms from SSRIs and SNRIs<\/p>\n<\/li>\n<\/ul>\n<p><span class=\"\"><span class=\"ms-1 inline-flex max-w-full items-center select-none relative top-[-0.094rem] translate-y-0.5 animate-[show_150ms_ease-in]\" style=\"width: 47px;\"><span class=\"flex h-4.5 overflow-hidden rounded-xl pe-2 ps-1 text-[9px] font-medium transition-colors duration-150 ease-in-out text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]! select-none\"><span class=\"relative start-0 bottom-0 flex h-full w-full items-center\"><span class=\"flex h-4 w-full items-center justify-between overflow-hidden\" style=\"opacity: 1; transform: none;\"><span class=\"flex min-w-0 flex-1 items-center gap-1\"><span class=\"inline-flex shrink-0 items-center justify-center overflow-hidden rounded-full\"><\/span><span class=\"max-w-[15ch] grow truncate overflow-hidden text-center\">PMC<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n<h3><span class=\"ez-toc-section\" id=\"4_Focus_on_Cognitive_Symptoms\"><\/span>4. Focus on Cognitive Symptoms<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Researchers increasingly recognized that successful depression treatment should address more than sadness.<\/p>\n<p>Clinical attention expanded toward improving:<\/p>\n<ul>\n<li>\n<p>Concentration<\/p>\n<\/li>\n<li>\n<p>Executive function<\/p>\n<\/li>\n<li>\n<p>Memory<\/p>\n<\/li>\n<li>\n<p>Motivation<\/p>\n<\/li>\n<li>\n<p>Fatigue<\/p>\n<\/li>\n<li>\n<p>Workplace functioning<\/p>\n<\/li>\n<\/ul>\n<p>Newer antidepressants such as <strong>vortioxetine<\/strong> received particular attention for potential cognitive benefits beyond mood improvement. <span class=\"\"><span class=\"ms-1 inline-flex max-w-full items-center select-none relative top-[-0.094rem] translate-y-0.5 animate-[show_150ms_ease-in]\" style=\"width: 47px;\"><span class=\"flex h-4.5 overflow-hidden rounded-xl pe-2 ps-1 text-[9px] font-medium transition-colors duration-150 ease-in-out text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]! select-none\"><span class=\"relative start-0 bottom-0 flex h-full w-full items-center\"><span class=\"flex h-4 w-full items-center justify-between overflow-hidden\" style=\"opacity: 1; transform: none;\"><span class=\"flex min-w-0 flex-1 items-center gap-1\"><span class=\"inline-flex shrink-0 items-center justify-center overflow-hidden rounded-full\"><\/span><span class=\"max-w-[15ch] grow truncate overflow-hidden text-center\">PMC<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n<h3><span class=\"ez-toc-section\" id=\"5_Personalized_Depression_Treatment\"><\/span>5. Personalized Depression Treatment<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Rather than applying a &#8220;one-size-fits-all&#8221; approach, clinicians increasingly emphasized individualized treatment based on:<\/p>\n<ul>\n<li>\n<p>Previous medication response<\/p>\n<\/li>\n<li>\n<p>Side-effect profile<\/p>\n<\/li>\n<li>\n<p>Anxiety symptoms<\/p>\n<\/li>\n<li>\n<p>Sleep disturbance<\/p>\n<\/li>\n<li>\n<p>Sexual dysfunction<\/p>\n<\/li>\n<li>\n<p>Cognitive impairment<\/p>\n<\/li>\n<li>\n<p>Patient preference<\/p>\n<\/li>\n<li>\n<p>Medical comorbidities<\/p>\n<\/li>\n<\/ul>\n<p>Precision psychiatry continued to gain momentum in both research and clinical practice. <span class=\"\"><span class=\"ms-1 inline-flex max-w-full items-center select-none relative top-[-0.094rem] translate-y-0.5 animate-[show_150ms_ease-in]\" style=\"width: 62px;\"><span class=\"flex h-4.5 overflow-hidden rounded-xl pe-2 ps-1 text-[9px] font-medium transition-colors duration-150 ease-in-out text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]! select-none\"><span class=\"relative start-0 bottom-0 flex h-full w-full items-center\"><span class=\"flex h-4 w-full items-center justify-between\" style=\"opacity: 1; transform: none;\"><span class=\"flex min-w-0 flex-1 items-center gap-1\"><span class=\"inline-flex shrink-0 items-center justify-center overflow-hidden rounded-full\"><\/span><span class=\"max-w-[15ch] grow truncate overflow-hidden text-center\">PMC<\/span><\/span><span class=\"-me-1 flex h-full items-center rounded-full px-1 text-[#8F8F8F]\">+1<\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Understanding_Newer_FDA-Approved_Oral_Antidepressants\"><\/span>Understanding Newer FDA-Approved Oral Antidepressants<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Three relatively newer oral antidepressants continued receiving attention during 2022:<\/p>\n<div class=\"TyagGW_tableContainer\"><div tabindex=\"-1\" class=\"group TyagGW_tableWrapper flex flex-col-reverse w-fit\"><table class=\"w-fit min-w-(--thread-content-width)\"><thead><tr><th class=\"last:pe-10\">Medication<\/th><th class=\"last:pe-10\">Unique Features<\/th><\/tr><\/thead><tbody><tr><td>Vortioxetine<\/td><td>Multimodal serotonin activity with possible cognitive benefits<\/td><\/tr><tr><td>Vilazodone<\/td><td>SSRI combined with partial 5-HT1A agonism<\/td><\/tr><tr><td>Levomilnacipran<\/td><td>Strong norepinephrine activity that may improve energy and motivation<\/td><\/tr><\/tbody><\/table><div class=\"relative h-0 self-end select-none\"><div class=\"absolute end-0 flex items-end\" style=\"height: 32.7969px;\"><span class=\"\"><button aria-label=\"\u0646\u0633\u062e \u0627\u0644\u062c\u062f\u0648\u0644\" class=\"hover:bg-token-bg-tertiary text-token-text-secondary relative z-10 my-1 rounded-sm p-1 transition-opacity group-[:not(:hover):not(:focus-within)]:pointer-events-none group-[:not(:hover):not(:focus-within)]:opacity-0\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"20\" height=\"20\" aria-hidden=\"true\" class=\"icon\"><use href=\"\/cdn\/assets\/sprites-core-91b3a79f.svg#ce3544\" fill=\"currentColor\"><\/use><\/svg><\/button><\/span><\/div><\/div><\/div><\/div>\n<p>These medications offer alternative options for selected patients but are not universally superior to older antidepressants. <span class=\"\"><span class=\"ms-1 inline-flex max-w-full items-center select-none relative top-[-0.094rem] translate-y-0.5 animate-[show_150ms_ease-in]\" style=\"width: 62px;\"><span class=\"flex h-4.5 overflow-hidden rounded-xl pe-2 ps-1 text-[9px] font-medium transition-colors duration-150 ease-in-out text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]! select-none\"><span class=\"relative start-0 bottom-0 flex h-full w-full items-center\"><span class=\"flex h-4 w-full items-center justify-between\" style=\"opacity: 1; transform: none;\"><span class=\"flex min-w-0 flex-1 items-center gap-1\"><span class=\"inline-flex shrink-0 items-center justify-center overflow-hidden rounded-full\"><\/span><span class=\"max-w-[15ch] grow truncate overflow-hidden text-center\">PMC<\/span><\/span><span class=\"-me-1 flex h-full items-center rounded-full px-1 text-[#8F8F8F]\">+1<\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Clinical_Challenges_Highlighted_in_2022\"><\/span>Clinical Challenges Highlighted in 2022<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Researchers also emphasized persistent limitations:<\/p>\n<ul>\n<li>\n<p>Approximately one-third of patients fail to achieve remission after initial treatment.<\/p>\n<\/li>\n<li>\n<p>Treatment-resistant depression remains a major clinical problem.<\/p>\n<\/li>\n<li>\n<p>Side effects continue to affect adherence.<\/p>\n<\/li>\n<li>\n<p>Predicting which antidepressant will work for an individual patient remains difficult. <span class=\"\"><span class=\"ms-1 inline-flex max-w-full items-center select-none relative top-[-0.094rem] translate-y-0.5 animate-[show_150ms_ease-in]\" style=\"width: 62px;\"><span class=\"flex h-4.5 overflow-hidden rounded-xl pe-2 ps-1 text-[9px] font-medium transition-colors duration-150 ease-in-out text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]! select-none\"><span class=\"relative start-0 bottom-0 flex h-full w-full items-center\"><span class=\"flex h-4 w-full items-center justify-between\" style=\"opacity: 1; transform: none;\"><span class=\"flex min-w-0 flex-1 items-center gap-1\"><span class=\"inline-flex shrink-0 items-center justify-center overflow-hidden rounded-full\"><\/span><span class=\"max-w-[15ch] grow truncate overflow-hidden text-center\">PMC<\/span><\/span><span class=\"-me-1 flex h-full items-center rounded-full px-1 text-[#8F8F8F]\">+1<\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Research_Pipeline\"><\/span>Research Pipeline<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Systematic reviews published during 2022 identified several promising investigational therapies, including:<\/p>\n<ul>\n<li>\n<p>Glutamate modulators<\/p>\n<\/li>\n<li>\n<p>NMDA receptor antagonists<\/p>\n<\/li>\n<li>\n<p>Triple reuptake inhibitors<\/p>\n<\/li>\n<li>\n<p>Psychedelic-assisted therapies (under investigation)<\/p>\n<\/li>\n<li>\n<p>Nitrous oxide<\/p>\n<\/li>\n<li>\n<p>Neurosteroid-based treatments<\/p>\n<\/li>\n<\/ul>\n<p>Most remained investigational and required additional large-scale clinical trials before widespread clinical use. <span class=\"\"><span class=\"ms-1 inline-flex max-w-full items-center select-none relative top-[-0.094rem] translate-y-0.5 animate-[show_150ms_ease-in]\" style=\"width: 62px;\"><span class=\"flex h-4.5 overflow-hidden rounded-xl pe-2 ps-1 text-[9px] font-medium transition-colors duration-150 ease-in-out text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]! select-none\"><span class=\"relative start-0 bottom-0 flex h-full w-full items-center\"><span class=\"flex h-4 w-full items-center justify-between\" style=\"opacity: 1; transform: none;\"><span class=\"flex min-w-0 flex-1 items-center gap-1\"><span class=\"inline-flex shrink-0 items-center justify-center overflow-hidden rounded-full\"><\/span><span class=\"max-w-[15ch] grow truncate overflow-hidden text-center\">PMC<\/span><\/span><span class=\"-me-1 flex h-full items-center rounded-full px-1 text-[#8F8F8F]\">+1<\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Clinical_Takeaway\"><\/span>Clinical Takeaway<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The most important advances in antidepressant therapy during 2022 included:<\/p>\n<ul>\n<li>\n<p>Expansion beyond traditional serotonin-focused medications.<\/p>\n<\/li>\n<li>\n<p>Greater emphasis on rapid-acting treatments.<\/p>\n<\/li>\n<li>\n<p>Development of medications targeting cognition, motivation, and functional recovery.<\/p>\n<\/li>\n<li>\n<p>Increasing adoption of personalized treatment strategies.<\/p>\n<\/li>\n<li>\n<p>Continued exploration of novel biological mechanisms that may improve outcomes for patients with difficult-to-treat depression. <span class=\"\"><span class=\"ms-1 inline-flex max-w-full items-center select-none relative top-[-0.094rem] translate-y-0.5 animate-[show_150ms_ease-in]\" style=\"width: 62px;\"><span class=\"flex h-4.5 overflow-hidden rounded-xl pe-2 ps-1 text-[9px] font-medium transition-colors duration-150 ease-in-out text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]! select-none\"><span class=\"relative start-0 bottom-0 flex h-full w-full items-center\"><span class=\"flex h-4 w-full items-center justify-between\" style=\"opacity: 1; transform: none;\"><span class=\"flex min-w-0 flex-1 items-center gap-1\"><span class=\"inline-flex shrink-0 items-center justify-center overflow-hidden rounded-full\"><\/span><span class=\"max-w-[15ch] grow truncate overflow-hidden text-center\">PMC<\/span><\/span><span class=\"-me-1 flex h-full items-center rounded-full px-1 text-[#8F8F8F]\">+2<\/span><\/span><span class=\"flex h-4 w-full items-center justify-between absolute\" style=\"opacity: 0; transform: translateX(10%);\"><span class=\"flex min-w-0 flex-1 items-center gap-1\"><span class=\"inline-flex shrink-0 items-center justify-center overflow-hidden rounded-full\"><\/span><span class=\"max-w-[15ch] grow truncate overflow-hidden text-center\">PMC<\/span><\/span><span class=\"-me-1 flex h-full items-center rounded-full px-1 text-[#8F8F8F]\">+2<\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n<\/li>\n<\/ul><\/div>\n<figure class=\"wch-inserted-image\"><img decoding=\"async\" width=\"1024\" height=\"683\" src=\"https:\/\/wniss.com\/wp-content\/uploads\/2026\/09\/reviewing-clinical-advances-in-latest-antidepressants-2022-2-WrPhHT-1024x683.webp\" alt=\"Reviewing Clinical Advances in Latest Antidepressants 2022 - Reviewing Clinical Advances in Latest\" loading=\"lazy\" class=\"wp-image-6092\" title=\"\" srcset=\"https:\/\/wniss.com\/wp-content\/uploads\/2026\/09\/reviewing-clinical-advances-in-latest-antidepressants-2022-2-WrPhHT-1024x683.webp 1024w, https:\/\/wniss.com\/wp-content\/uploads\/2026\/09\/reviewing-clinical-advances-in-latest-antidepressants-2022-2-WrPhHT-300x200.webp 300w, https:\/\/wniss.com\/wp-content\/uploads\/2026\/09\/reviewing-clinical-advances-in-latest-antidepressants-2022-2-WrPhHT-150x100.webp 150w, https:\/\/wniss.com\/wp-content\/uploads\/2026\/09\/reviewing-clinical-advances-in-latest-antidepressants-2022-2-WrPhHT-100x67.webp 100w, https:\/\/wniss.com\/wp-content\/uploads\/2026\/09\/reviewing-clinical-advances-in-latest-antidepressants-2022-2-WrPhHT-200x133.webp 200w, https:\/\/wniss.com\/wp-content\/uploads\/2026\/09\/reviewing-clinical-advances-in-latest-antidepressants-2022-2-WrPhHT-250x167.webp 250w, https:\/\/wniss.com\/wp-content\/uploads\/2026\/09\/reviewing-clinical-advances-in-latest-antidepressants-2022-2-WrPhHT-350x233.webp 350w, https:\/\/wniss.com\/wp-content\/uploads\/2026\/09\/reviewing-clinical-advances-in-latest-antidepressants-2022-2-WrPhHT-400x267.webp 400w, https:\/\/wniss.com\/wp-content\/uploads\/2026\/09\/reviewing-clinical-advances-in-latest-antidepressants-2022-2-WrPhHT-500x333.webp 500w, https:\/\/wniss.com\/wp-content\/uploads\/2026\/09\/reviewing-clinical-advances-in-latest-antidepressants-2022-2-WrPhHT-600x400.webp 600w, https:\/\/wniss.com\/wp-content\/uploads\/2026\/09\/reviewing-clinical-advances-in-latest-antidepressants-2022-2-WrPhHT.webp 1200w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure><figure class=\"wch-inserted-image\"><img decoding=\"async\" width=\"1024\" height=\"683\" src=\"https:\/\/wniss.com\/wp-content\/uploads\/2026\/09\/reviewing-clinical-advances-in-latest-antidepressants-2022-3-vVUbMg-1024x683.webp\" alt=\"Reviewing Clinical Advances in Latest Antidepressants 2022 - Reviewing Clinical Advances in Latest\" loading=\"lazy\" class=\"wp-image-6093\" title=\"\" srcset=\"https:\/\/wniss.com\/wp-content\/uploads\/2026\/09\/reviewing-clinical-advances-in-latest-antidepressants-2022-3-vVUbMg-1024x683.webp 1024w, https:\/\/wniss.com\/wp-content\/uploads\/2026\/09\/reviewing-clinical-advances-in-latest-antidepressants-2022-3-vVUbMg-300x200.webp 300w, https:\/\/wniss.com\/wp-content\/uploads\/2026\/09\/reviewing-clinical-advances-in-latest-antidepressants-2022-3-vVUbMg-150x100.webp 150w, https:\/\/wniss.com\/wp-content\/uploads\/2026\/09\/reviewing-clinical-advances-in-latest-antidepressants-2022-3-vVUbMg-100x67.webp 100w, https:\/\/wniss.com\/wp-content\/uploads\/2026\/09\/reviewing-clinical-advances-in-latest-antidepressants-2022-3-vVUbMg-200x133.webp 200w, https:\/\/wniss.com\/wp-content\/uploads\/2026\/09\/reviewing-clinical-advances-in-latest-antidepressants-2022-3-vVUbMg-250x167.webp 250w, https:\/\/wniss.com\/wp-content\/uploads\/2026\/09\/reviewing-clinical-advances-in-latest-antidepressants-2022-3-vVUbMg-350x233.webp 350w, https:\/\/wniss.com\/wp-content\/uploads\/2026\/09\/reviewing-clinical-advances-in-latest-antidepressants-2022-3-vVUbMg-400x267.webp 400w, https:\/\/wniss.com\/wp-content\/uploads\/2026\/09\/reviewing-clinical-advances-in-latest-antidepressants-2022-3-vVUbMg-500x333.webp 500w, https:\/\/wniss.com\/wp-content\/uploads\/2026\/09\/reviewing-clinical-advances-in-latest-antidepressants-2022-3-vVUbMg-600x400.webp 600w, https:\/\/wniss.com\/wp-content\/uploads\/2026\/09\/reviewing-clinical-advances-in-latest-antidepressants-2022-3-vVUbMg.webp 1200w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>","protected":false},"excerpt":{"rendered":"<p>Reviewing Clinical Advances in Latest Antidepressants (2022) The year 2022 marked an important period in antidepressant research. While traditional SSRIs, SNRIs, and [&hellip;]<\/p>\n","protected":false},"author":11,"featured_media":6091,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[730],"tags":[],"class_list":["post-4251","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-depression"],"acf":[],"_links":{"self":[{"href":"https:\/\/wniss.com\/en-gb\/wp-json\/wp\/v2\/posts\/4251","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/wniss.com\/en-gb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/wniss.com\/en-gb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/wniss.com\/en-gb\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/wniss.com\/en-gb\/wp-json\/wp\/v2\/comments?post=4251"}],"version-history":[{"count":2,"href":"https:\/\/wniss.com\/en-gb\/wp-json\/wp\/v2\/posts\/4251\/revisions"}],"predecessor-version":[{"id":6094,"href":"https:\/\/wniss.com\/en-gb\/wp-json\/wp\/v2\/posts\/4251\/revisions\/6094"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/wniss.com\/en-gb\/wp-json\/wp\/v2\/media\/6091"}],"wp:attachment":[{"href":"https:\/\/wniss.com\/en-gb\/wp-json\/wp\/v2\/media?parent=4251"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/wniss.com\/en-gb\/wp-json\/wp\/v2\/categories?post=4251"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/wniss.com\/en-gb\/wp-json\/wp\/v2\/tags?post=4251"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}